Suppr超能文献

对原发性不可切除、局部复发或大体切除不完全的胃腺癌进行放疗或放化疗的结果。

Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma.

作者信息

Henning G T, Schild S E, Stafford S L, Donohue J H, Burch P A, Haddock M G, Gunderson L L

机构信息

Division of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.

出版信息

Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):109-18. doi: 10.1016/s0360-3016(99)00379-x.

Abstract

OBJECTIVE

To evaluate the results of irradiation +/- chemotherapy for patients with unresectable gastric carcinoma.

MATERIALS AND METHODS

The records of 60 patients with a gastric or gastroesophageal junction adenocarcinoma and a locally advanced unresectable primary (n = 28), a local or regional recurrence (n = 21), or gross residual disease following incomplete resection (n = 11) were retrospectively reviewed. Patients were treated with external beam irradiation (EBRT) alone or external beam plus intraoperative irradiation (IOERT), and 55 of the 60 (92%) patients received 5-FU based chemotherapy.

RESULTS

The median survival for the entire cohort was 11.6 months. There was no significant difference in median survival between each of the three treatment groups. In examining the extent of disease there was a significant difference in survival based on the number of sites involved. Nine patients with disease limited to a single non-nodal site appeared to represent a favorable subgroup compared to the rest of the patients (median survival of 21.8 months vs. 10.2 months,p = 0.03). In the patients with recurrent disease, the number of sites involved (p = 0.05), and total dose adding external beam dose to IOERT dose (> 54 Gy vs. < or =54 Gy, p = 0.06) were of borderline significance in regard to survival.

CONCLUSIONS

In patients with either primary unresectable, locally or regionally recurrent, or incompletely resected gastric carcinoma, the overall survival is similar, and related to the extent of disease based on the number of regional sites involved. The patients with a single non-nodal site of disease represent a favorable subgroup and patients with recurrent disease may benefit from total irradiation doses > 54 Gy.

摘要

目的

评估不可切除胃癌患者接受放疗±化疗的效果。

材料与方法

回顾性分析60例胃或胃食管交界腺癌患者的记录,这些患者存在局部晚期不可切除的原发肿瘤(n = 28)、局部或区域复发(n = 21)或不完全切除后的大体残留病灶(n = 11)。患者接受单纯外照射放疗(EBRT)或外照射加术中放疗(IOERT),60例患者中有55例(92%)接受了基于5-氟尿嘧啶的化疗。

结果

整个队列的中位生存期为11.6个月。三个治疗组各自的中位生存期无显著差异。在检查疾病范围时,根据受累部位数量,生存期存在显著差异。与其他患者相比,9例疾病局限于单个非淋巴结部位的患者似乎代表一个有利的亚组(中位生存期分别为21.8个月和10.2个月,p = 0.03)。在复发疾病患者中,受累部位数量(p = 0.05)以及外照射剂量与IOERT剂量之和的总剂量(> 54 Gy与≤54 Gy,p = 0.06)对生存期具有临界显著性意义。

结论

对于原发性不可切除、局部或区域复发或不完全切除的胃癌患者,总体生存期相似,并与基于受累区域部位数量的疾病范围相关。疾病局限于单个非淋巴结部位的患者代表一个有利的亚组,复发疾病患者可能从总照射剂量> 54 Gy中获益。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验